WDFY2: A Potential Drug Target Or Biomarker (G115825)
WDFY2: A Potential Drug Target Or Biomarker
WDFY2, a protein that belongs to the Wnt signaling pathway, has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative disorders, and developmental defects. Its unique structure and function have made it an attractive target for researchers to study, and its potential applications in drug development have gained significant attention in recent years.
The Wnt signaling pathway is a critical regulator of development and growth, and it is involved in the formation and maintenance of tissues and organs during embryonic development. The pathway is composed of several proteins, including Wnt, Fz, and Lr, which are involved in the formation of the axial nervous system, the development of limbs, and the formation of the placenta.
WDFY2 is a protein that is expressed in various tissues and organs, including the brain, spinal cord, heart, and kidneys. It is a 21-kDa protein that is composed of 115 amino acid residues. WDFY2 is highly conserved, with a high degree of sequence identity between its human and mouse counterparts.
WDFY2 plays a crucial role in the Wnt signaling pathway in the development and maintenance of tissues and organs. It is involved in the formation of the axial nervous system, which is responsible for the development of the arms and legs. WDFY2 is also involved in the formation of the neural tube, which gives rise to the brain and spinal cord.
In addition to its role in the Wnt signaling pathway, WDFY2 has also been shown to play a role in the development and maintenance of various tissues and organs. For example, studies have shown that WDFY2 is involved in the development and maintenance of the heart, the kidneys, and the liver. It is also involved in the regulation of inflammation, and has been shown to play a role in the immune response.
WDFY2 has also been shown to be a potential drug target or biomarker for various diseases, including cancer, neurodegenerative disorders, and developmental defects. For example, studies have shown that WDFY2 is involved in the development and progression of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. It is also involved in the development and progression of cancer, including breast and ovarian cancer.
In addition to its potential clinical applications, WDFY2 has also generated significant interest among researchers due to its unique structure and function. The high degree of sequence identity between WDFY2 and its mouse and human counterparts has made it an attractive target for researchers to study, and its unique expression patterns in various tissues have provided valuable insights into its function in development and maintenance.
Overall, WDFY2 is a protein that has significant potential as a drug target or biomarker for various diseases. Its unique structure and function have made it an attractive target for researchers to study, and its potential applications in drug development have gained significant attention in recent years. Further research is needed to fully understand the role of WDFY2 in development and maintenance of tissues and organs, and to develop effective treatments for various diseases.
Protein Name: WD Repeat And FYVE Domain Containing 2
Functions: Acts in an adapter protein-like fashion to mediate the interaction between the kinase PRKCZ and its substrate VAMP2 and increases the PRKCZ-dependent phosphorylation of VAMP2 (PubMed:17313651). Positively regulates adipocyte differentiation, by facilitating the phosphorylation and thus inactivation of the anti-adipogenetic transcription factor FOXO1 by the kinase AKT1 (PubMed:18388859). Plays a role in endosomal control of AKT2 signaling; required for insulin-stimulated AKT2 phosphorylation and glucose uptake and insulin-stimulated phosphorylation of AKT2 substrates (By similarity). Participates in transferrin receptor endocytosis (PubMed:16873553)
The "WDFY2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WDFY2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
WDFY3 | WDFY3-AS2 | WDFY4 | WDHD1 | WDPCP | WDR1 | WDR11 | WDR11-DT | WDR12 | WDR13 | WDR17 | WDR18 | WDR19 | WDR20 | WDR24 | WDR25 | WDR26 | WDR27 | WDR3 | WDR31 | WDR33 | WDR35 | WDR35-DT | WDR36 | WDR37 | WDR38 | WDR4 | WDR41 | WDR43 | WDR44 | WDR45 | WDR45B | WDR46 | WDR47 | WDR48 | WDR49 | WDR5 | WDR53 | WDR54 | WDR55 | WDR59 | WDR5B | WDR6 | WDR62 | WDR64 | WDR7 | WDR70 | WDR72 | WDR73 | WDR74 | WDR75 | WDR76 | WDR77 | WDR81 | WDR82 | WDR82P1 | WDR83 | WDR83OS | WDR86 | WDR86-AS1 | WDR87 | WDR88 | WDR89 | WDR90 | WDR91 | WDR93 | WDR97 | WDSUB1 | WDTC1 | WEE1 | WEE2 | WEE2-AS1 | WFDC1 | WFDC10A | WFDC10B | WFDC11 | WFDC12 | WFDC13 | WFDC2 | WFDC21P | WFDC3 | WFDC5 | WFDC6 | WFDC8 | WFDC9 | WFIKKN1 | WFIKKN2 | WFS1 | WHAMM | WHAMMP1 | WHAMMP2 | WHAMMP3 | WHRN | WIF1 | WIPF1 | WIPF2 | WIPF3 | WIPI1 | WIPI2 | WIZ
